CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 110 enrolled
Drug / intervention
Nifedipine 30 MG +1 moredrug
Likely dose
Nifedipine 30 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04392375
NCT04392375Phase 4Completed
CompareCT.gov

Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor

Ohio State University·interventional·Posted May 18, 2020·Updated Jul 24, 2023

In Brief

A Phase 4 clinical trial evaluating Nifedipine 30 MG and Placebos for Preeclampsia Severe. Completed, enrolled 110 participants across 1 site.

Detailed Summary

This is a randomized double blind placebo controlled trial comparing Nifedipine 30mg XL to placebo in 110 patients after decision has been made to proceed with induction of labor for the diagnosis of preeclampsia with severe features.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPreeclampsia Severe
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedMay 18, 2020
Enrollment StartJun 9, 2020
Primary CompletionApr 20, 2022
Study CompletionMay 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.1 years ago

Interventions

Nifedipine 30 MGdrug

Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.

Placebosdrug

At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.